retatrutide weight loss efficacy 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲: a new triple-agonist drug that is STILL IN CLINICAL TRIALS, is showing incredible results, with some 🚨 TRIUMPH-1: #retatrutide topline data🚨

After the knockout of the GLP-1R gene, in transgenic mice expressing human GLP-1R in pancreatic islets and pancreatic ductal cells restored cAMP and serine threonine kinase (Akt) phosphorylation levels in isolated islets, increased GLP-1-stimulated insulin secretion and GLP-1R-dependent -cell proliferation, and promoted transgenic mice for glucose regulation in response to feeding (Lamont et al., 2012)

Transcend 1 was a 40 week double blinded trial testing 4mg, 9mg, 12mg retatrutide vs placebo

Manufacturers struggled to keep up with the surge in demand for the injectable GLP-1 agonist medications, but now this provides another option in the marketplace. Ozempic pills could be a huge catalyst for the GLP-1 industry While injectable medications may be slightly more effective, pills are easier to take and still result in weight loss

The Foundayo pill will be available in six different doses, in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg tablets

Fujita H, Morii T, Fujishima H, et al

Graphical Abstract Keywords NAFLD, MASLD, Clinical trial, Medication, Hypoglycemic agents, Intermediary metabolism Introduction In 2020, a group of experts aimed to integrate the understanding of patient heterogeneity and more accurately highlight disease pathogenesis captured under the acronym non-alcoholic fatty liver disease (NAFLD)